Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IRD

Opus Genetics Inc

Mar 09 • 04:00PM ET

4.77

-0.12 -2.45 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	24.72%	Shs Outstand	64.54M	Perf Week	10.16%
Market Cap	328.95M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-18.37%	Shs Float	51.91M	Perf Month	84.88%
Enterprise Value	299.20M	PEG	-	EPS next Q	-0.11	Inst Own	35.01%	Short Float	1.81%	Perf Quarter	113.90%
Income	-68.20M	P/S	22.48	EPS this Y	33.37%	Inst Trans	7.47%	Short Ratio	1.10	Perf Half Y	275.59%
Sales	14.63M	P/B	51.60	EPS next Y	-15.44%	ROA	-178.28%	Short Interest	0.94M	Perf YTD	137.31%
Book/sh	0.09	P/C	10.67	EPS next 5Y	6.94%	ROE	-338.75%	52W High	5.10 -6.47%	Perf Year	377.76%
Cash/sh	0.45	P/FCF	-	EPS past 3/5Y	17.37% 24.32%	ROIC	-969.48%	52W Low	0.65 633.85%	Perf 3Y	34.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	165.25% -	Gross Margin	99.66%	Volatility	9.49% 9.64%	Perf 5Y	-47.52%
Dividend TTM	-	EV/Sales	20.45	EPS Y/Y TTM	-58.14%	Oper. Margin	-254.05%	ATR (14)	0.34	Perf 10Y	-97.31%
Dividend Ex-Date	-	Quick Ratio	1.23	Sales Y/Y TTM	74.60%	Profit Margin	-466.09%	RSI (14)	73.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.23	EPS Q/Q	14.17%	SMA20	22.76%	Beta	0.54	Target Price	8.82
Payout	-	Debt/Eq	0.18	Sales Q/Q	-20.38%	SMA50	63.29%	Rel Volume	1.42	Prev Close	4.89
Employees	18	LT Debt/Eq	0.18	Earnings	Feb 25	SMA200	156.33%	Avg Volume	854.26K	Price	4.77
IPO	Nov 30, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.92% 10.44%	Trades		Volume	1,216,725	Change	-2.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-20-26	Initiated	BTIG Research	Buy	$7
Dec-10-25	Initiated	B. Riley Securities	Buy	$9
Nov-25-25	Initiated	Piper Sandler	Overweight	$7
Oct-29-25	Initiated	Wedbush	Outperform	$8
Oct-16-25	Initiated	Chardan Capital Markets	Buy	$9
Apr-11-25	Initiated	Craig Hallum	Buy	$6
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +7.53%
Mar-03-26 08:00AM	Opus Genetics to Present at Upcoming Investor Conferences in March 2026 (GlobeNewswire)
Feb-27-26 10:10AM	Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting (GlobeNewswire) +15.88%
Feb-25-26 06:59AM	Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire)
Feb-13-26 07:30AM	Opus Genetics Announces $25 Million Private Placement (GlobeNewswire) +7.37%
08:00AM	Loading…
Feb-02-26 08:00AM	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 (GlobeNewswire)
Jan-27-26 07:00AM	Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa (GlobeNewswire)
Jan-09-26 07:20AM	Opus Genetics highlights 2025 progress, upcoming 2026 catalysts (TipRanks)
Jan-08-26 07:00AM	Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts (GlobeNewswire) -5.21%
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-16-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.61%
Dec-11-25 07:00AM	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-09-25 07:00AM	Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease (GlobeNewswire)
Dec-02-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Nov-29-25 01:26AM	Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With "Overweight" Rating and $7 PT (Insider Monkey)
08:00AM	Loading…
Nov-20-25 08:00AM	Opus Genetics to Participate in Upcoming Investment Conferences (GlobeNewswire)
Nov-13-25 07:00AM	Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease (GlobeNewswire)
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease (GlobeNewswire)
07:00AM	Opus Genetics Announces $23 Million Registered Direct Offering (GlobeNewswire)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:40AM	Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates (Zacks)
Nov-04-25 05:15PM	Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 08:00AM	Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness (GlobeNewswire) -6.96%
Oct-14-25 08:00AM	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-02-25 08:00AM	Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 (GlobeNewswire)
12:00PM	Loading…
Oct-01-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice (Zacks) +9.09%
Sep-30-25 07:00AM	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) (GlobeNewswire) -7.82%
Sep-16-25 03:42AM	Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics (Zacks)
Sep-15-25 03:00PM	The Under $20 Breakout Trio Investors Shouldn't Ignore (Zacks)
Sep-12-25 08:00AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-25 08:00AM	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire)
Sep-03-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer (GlobeNewswire)
Aug-27-25 08:00AM	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 (GlobeNewswire)
Aug-13-25 05:40PM	Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.27%
04:30PM	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-23-25 08:00AM	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-03-25 04:30PM	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-25 06:55AM	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire) +5.13%
Jun-23-25 08:00AM	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program (GlobeNewswire)
Jun-02-25 08:00AM	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire) +9.60%
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 08:00AM	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 08:00AM	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate (GlobeNewswire)
May-05-25 08:00AM	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
Apr-15-25 10:36AM	PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath (GlobeNewswire)
Apr-11-25 03:47PM	Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns (GlobeNewswire)
Apr-08-25 08:00AM	Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases (GlobeNewswire) -11.50%
Apr-07-25 08:00AM	Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress (GlobeNewswire)
Apr-02-25 08:00AM	Opus Genetics to Participate in Upcoming Investor Conference in April (GlobeNewswire)
Mar-31-25 08:20AM	Opus Genetics Announces Financial Results for Full Year 2024 (GlobeNewswire)
Mar-21-25 05:03PM	Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics (GlobeNewswire) +9.57% -8.73%
09:30AM	Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX (GlobeNewswire)
09:11AM	Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million (GlobeNewswire)
Mar-19-25 03:56PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 08:00AM	Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
Feb-26-25 08:00AM	Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs (GlobeNewswire)
Feb-18-25 07:30AM	Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program (GlobeNewswire)
Feb-07-25 09:15AM	Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. (GlobeNewswire) -5.74%
Dec-19-24 08:00AM	Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy (GlobeNewswire) +18.93%
Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
Aug-13-24 08:00AM	Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire) -20.85%
Aug-08-24 08:00AM	Ocuphire Pharma to Present at Two Investor Conferences in August (GlobeNewswire) +6.10%
Jul-10-24 08:00AM	Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July (GlobeNewswire) +6.45%
Jun-06-24 07:57AM	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June (GlobeNewswire)
May-10-24 01:53PM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.24%
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting (GlobeNewswire)
May-03-24 08:00AM	Ocuphire Pharma to Present at the Aegis Virtual Conference (GlobeNewswire) +7.57%
Apr-22-24 08:00AM	Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting (GlobeNewswire) -8.76%
Apr-11-24 10:03AM	First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery (GlobeNewswire)
Apr-01-24 07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire) +10.95%
Mar-15-24 11:53AM	OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 08:00AM	Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update (GlobeNewswire) -16.39%
Mar-04-24 08:18AM	Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-23-24 08:00AM	Ocuphire Pharma to Present in the BIO CEO & Investor Conference (GlobeNewswire)

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gallagher Cam	Director	Dec 29 '25	Buy	1.97	83,000	163,419	83,000	Dec 31 04:33 PM
Gallagher Cam	Director	Dec 29 '25	Buy	1.98	81,000	160,275	1,891,430	Dec 31 04:33 PM
Foundation Fighting Blindness	Director	Dec 09 '25	Sale	2.15	4,000,000	8,600,000	5,492,171	Dec 11 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRD

Opus Genetics Inc

Upgrade your FINVIZ experience